General Fusion and TRIUMF sign MOU to develop key technologies for new LM26 fusion machine 25-10-2023, 20:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Bitget Protection Fund Maintains Strength with $561 Million Average Value in April 2025 14-05-2025, 17:00